Table 1.
Distribution of baseline characteristics between right-sided and left-sided metastatic colorectal cancer among 161 patients
| All (n = 161) | Right-sided mCRC (n = 38) | Left-sided mCRC (n = 123) | p-value | |
|---|---|---|---|---|
| Sex | ||||
| Malea | 103 (64) | 26 (68) | 77 (63) | 0.646 |
| Femalea | 58 (36) | 12 (32) | 46 (37) | |
| Median age at diagnosis of metastatic disease | ||||
| (range)a | 65 (35–85) | 67.5 (35–85) | 65 (39–84) | 0.127d |
| Grading | 161 (100) | |||
| I | 1 (1) | 0 (0) | 1 (1) | 1.000 |
| IIa | 102 (63) | 25 (66) | 77 (63) | |
| IIIa | 51 (32) | 13 (34) | 38 (31) | |
| Not available | 7 | 0 | 7 | |
| Detection of metastases | ||||
| Synchronousa | 108 (67) | 28 (74) | 80 (65) | 0.427 |
| Metachronousa | 53 (33) | 10 (26) | 43 (35) | |
| Histologic subtype | ||||
| Non-mucinousa | 143 (89) | 30 (79) | 113 (92) | 0.038c |
| Mucinousa | 18 (11) | 8 (21) | 10 (8) | |
| Location of first metastases | ||||
| Liverb,e | 108 (67) | 28 (74) | 80 (65) | 0.427 |
| Lungb,e | 51 (32) | 7 (18) | 44 (36) | 0.070 |
| Peritoneumb,e | 31 (19) | 9 (24) | 22 (18) | 0.578 |
| Otherb,e | 38 (24) | 11 (29) | 27 (22) | 0.503 |
| Liver and peritoneumb,e | 15 (9) | 4 (11) | 11 (9) | 0.754c |
| Liver-limited metastases | ||||
| Yesa | 59 (37) | 14 (37) | 45 (37) | 1.000 |
| Noa | 102 (63) | 24 (63) | 78 (63) | |
| First-line systemic therapy | ||||
| Anti-VEGF basedb | 79 (49) | 20 (53) | 59 (48) | 0.751 |
| Bevacizumab | 76 | 20 | 56 | |
| Aflibercept | 3 | 0 | 3 | |
| Anti-EGFR basedb | 30 (19) | 8 (21) | 22 (18) | 0.781 |
| Cetuximab | 20 | 5 | 15 | |
| Panitumumab | 10 | 3 | 7 | |
| Chemotherapy onlyb | 41 (25) | 9 (24) | 32 (26) | 0.940 |
| No systemic therapy | 11 (7) | 1 (2) | 10 (8) | |
| Metastasectomy with curative intent | ||||
| Yesa | 36 (22) | 5 (13) | 31 (25) | 0.197 |
| Noa | 123 (77) | 32 (84) | 91 (74) | |
| Not available | 2 (1) | 1 (3) | 1 (1) | |
| Chemotherapy backbone | ||||
| Oxaliplatina | 91 (56) | 24 (63) | 67 (55) | 0.712 |
| Irinotecana | 40 (25) | 9 (23) | 31 (25) | |
| 5-FU/Capecitabine monoa | 19 (12) | 4 (11) | 15 (12) | |
| No Chemotherapya | 11 (7) | 1 (3) | 10 (8) | |
Percentage in brackets, aincluded categories, bnumber of patients in individual categories versus all other patients in the respective group, ctwo-sided Fisher’s exact test, dtwo-sided Wilcoxon rank-sum test, emultiple designations are possible, Χ2-test with Yates’ correction in all other cases